TOPROL-XL Drug Patent Profile

When do Toprol-xl patents expire, and when can generic versions of Toprol-xl launch?

Toprol-xl is a drug marketed by Melinta Therap and is included in one NDA.

The generic ingredient in TOPROL-XL is metoprolol succinate. There are sixty drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Toprol-xl

A generic version of TOPROL-XL was approved as metoprolol succinate by ACTAVIS LABS FL INC on August 3^rd, 2009.

Summary for TOPROL-XL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	22
Patent Applications:	2,666
DailyMed Link:	TOPROL-XL at DailyMed

Recent Clinical Trials for TOPROL-XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AgoneX Biopharmaceuticals, Inc.	Phase 2
BioHealthonomics Inc.	Phase 2
Medtronic	Phase 2

See all TOPROL-XL clinical trials

Pharmacology for TOPROL-XL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TOPROL-XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-004	Feb 5, 2001	AB	RX	Yes	No
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-003	Jan 10, 1992	AB	RX	Yes	Yes
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-001	Jan 10, 1992	AB	RX	Yes	Yes

Expired US Patents for TOPROL-XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-002	Jan 10, 1992
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-003	Jan 10, 1992
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-001	Jan 10, 1992

International Patents for TOPROL-XL

See the table below for patents covering TOPROL-XL around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3586206
Latvia	5751	Farmaceitisks preparats
South Africa	8609860

Market Dynamics and Financial Trajectory for TOPROL-XL

Last updated: February 20, 2026

What is TOPROL-XL?

TOPROL-XL (metoprolol succinate) is a beta-blocker indicated primarily for treatment of hypertension, angina pectoris, and heart failure. It is a sustained-release formulation marketed by AstraZeneca, with a patent expiring in multiple jurisdictions by 2017 and generic versions entering the market thereafter.

How has the market for TOPROL-XL evolved?

The global beta-blocker segment, including TOPROL-XL, experienced steady growth driven by the prevalence of cardiovascular diseases. Key drivers include:

• Rising cardiovascular disease (CVD) prevalence: Omnibus data show over 350 million people globally suffer from hypertension, a primary indication for TOPROL-XL (World Health Organization, 2021).
• Shift from branded to generic formulations: Patent expiry led to increased generic competition, impacting revenues.
• Treatment guideline updates: Clinical guidelines recommend beta-blockers as first-line or adjunct therapy for certain CVD indications, supporting sustained demand.
• Geographic expansion: Increasing adoption in emerging markets due to healthcare infrastructure improvements.

What factors influence TOPROL-XL’s financial trajectory?

Patent Expiry and Generic Competition

The patent expiry for TOPROL-XL occurred in 2017 in the US, leading to the appearance of multiple generic equivalents. Generics typically capture over 80% of market share within two years, reducing branded sales substantially.

Pricing Dynamics

Brand-name pharmaceuticals often command premiums of 30-50% over generics. The entry of generics resulted in price reductions up to 70% for TOPROL-XL, pressuring revenue streams.

Market Volume Trends

Global demand for beta-blockers remains stable or grows slightly, with volume increases in emerging markets. However, the overall value contribution of TOPROL-XL diminishes as generics dominate sales.

Competitive Landscape

• Generic Manufacturers: Several global and regional companies supply metoprolol succinate.
• Biosimilars and Alternative Agents: While biosimilars do not directly compete with TOPROL-XL, the presence of alternative beta-blockers (e.g., carvedilol, atenolol) influences prescribing habits.

Regulatory and Policy Environment

Health authorities encourage cost-effective treatments, favoring generics. Reimbursement policies and formulary preferences shift toward lower-cost options, impacting TOPROL-XL's market share.

Market Size and Forecast

Prior to patent expiry, US sales averaged approximately $400 million annually (IQVIA, 2016). Post-patent, sales declined sharply. Current estimates project U.S. generic metoprolol succinate sales to reach $2 billion in 2025 globally, but branded TOPROL-XL’s share will remain limited, likely below $100 million annually.

How do future trends influence TOPROL-XL?

Rise of New Agents and Fixed-Dose Combinations

Newer drugs and combinations (e.g., β-blockers combined with vasodilators) could cannibalize demand for traditional metoprolol formulations. Clinical trial outcomes favoring alternatives may further erode TOPROL-XL sales.

Technological and Formulation Innovations

Emerging delivery systems or biosimilar-like competition might reshape market shares, though no significant changes are imminent for TOPROL-XL specifically.

Market Focus on Value and Cost-Effectiveness

Healthcare payers emphasize medicines with proven outcomes and lower costs, directing formulary preference toward generic metoprolol.

Summary of Financial Outlook

Timeframe	Key Financial Factors	Projection
2023–2025	Continued generic penetration, price reductions, market saturation	Low or declining revenue for TOPROL-XL branded sales; overall beta-blocker market stabilizes at lower margins
2026–2030	Entry of biosimilars, competing agents, evolving treatment protocols	Virtually no branded TOPROL-XL sales; focus shifts to generic revenues and pipeline development

Key Takeaways

• Patent expiry in 2017 caused a steep decline in TOPROL-XL sales in major markets.
• Generic competition dominates the market, leading to significant price erosion.
• The overall beta-blocker market is stable, driven by CVD prevalence.
• Future demand for TOPROL-XL remains limited due to shifts toward newer agents and formulary preferences.
• Investment in pipeline products targeting resistant or special populations offers the most growth potential.

FAQs

1. Has TOPROL-XL been replaced by newer drugs?
Yes. While still prescribed, its market share decreases as clinicians adopt newer beta-blockers and combination therapies.

2. Are there any current patent protections or exclusivities for TOPROL-XL?
The initial patent expired in 2017; no active exclusivities remain. Generics dominate the market.

3. What is the global market size for TOPROL-XL?
Current branded TOPROL-XL sales are estimated below $100 million globally, primarily in the U.S. and select markets.

4. How do pricing trends affect future revenues?
Pricing has declined sharply post-generic entry, with little room for recovery in branded sales.

5. What opportunities exist for branded formulations?
Niche markets, such as formulations for specific patient populations or combination therapies, present limited opportunities due to competition and market saturation.

---

References

[1] World Health Organization. (2021). Global status report on noncommunicable diseases.
[2] IQVIA. (2016). U.S. pharmaceutical sales report.
[3] U.S. Food and Drug Administration. (2017). Patent expirations and generic entry data.